https://www.ft.com/content/fa1e0d22-71f2-401f-9971-fa27313570ab Vaccine makers say IP waiver could hand technology to China and Russia Proposal to suspend patent rights comes as poorer countries struggle to obtain Covid doses Vaccine makers have warned US officials that temporarily scrapping patents for Covid-19 shots would risk handing novel technology to China and Russia, according to people familiar with the talks. As industry lobbying has escalated in Washington, companies have warned in private meetings with US trade and White House officials that giving up the intellectual property rights could allow China and Russia to exploit platforms such as mRNA, which could be used for other vaccines or even therapeutics for conditions such as cancer and heart problems in the future. J&J, Pfizer, Moderna and Novavax did not respond to requests for comment. A measure to allow countries to temporarily override patent rights for pandemic-related medical products was proposed at the World Trade Organization by India and South Africa in October, and has since been backed by almost 60 countries. While Donald Trump’s administration firmly opposed the waiver at the WTO, along with the UK, EU and Switzerland, US president Joe Biden’s top trade official Katherine Tai has rattled US pharmaceutical companies by appearing to put that position under review. Recommended Covid-19 vaccines Covid-19 vaccine tracker: the global race to vaccinate Tai and her staff have in recent weeks discussed the WTO’s IP rules with pharma companies, trade unions, advocacy groups and Seth Berkley, chief executive of the UN-backed vaccine alliance Gavi. Her office has said the agency was “exploring every avenue” and “evaluating the efficacy” of the waiver. In a speech to a WTO meeting on vaccine equity earlier this month, Tai said that both the government and the private sector would need to do their part to “live up to” the “spirit” of the Trade-Related Aspects of Intellectual Property Rights (Trips) agreement, which was born out of the HIV crisis. “We hope to hear more today about how the market once again has failed in meeting the health needs of developing countries,” Tai told the WTO meeting. “As part of that, we have to consider what modifications and reforms to our trade rules might be necessary to reflect what we have learned.” Her speech has increased tension between pharma companies and the US trade representative (USTR), prompting one vaccine maker to complain to White House officials about Tai’s remarks to the WTO. The White House did not respond to a request for comment. The USTR said its “top priority” was “saving lives” and that it was “working with our global partners to explore pragmatic and effective steps to surge the production and equitable distribution of vaccines”. The debate at the WTO about whether to temporarily waive intellectual protections comes amid concerns that rich countries are vaccinating their populations significantly faster than developing economies, which have struggled to obtain the required doses. However, pharmaceutical companies insist they are already doing everything they can to expand production, and that global manufacturing bottlenecks, not patents, are slowing the rate at which vaccines are produced. The battle over IP comes as drugmakers are once again under pressure domestically, as drug pricing reform moves up the Biden administration's agenda. This includes proposals to peg drug prices to those in other industrialised nations, which are usually far cheaper, and allowing Medicare, the pension plan for older people, to negotiate prices. The Chinese and Russian vaccines use different approaches from mRNA, the technology first deployed in an approved product for a Covid-19 vaccine. Recommended InterviewCovid-19 vaccines Vaccine patent gives US government ‘leverage’ over manufacturers While Russia’s Sputnik showed robust efficacy in a peer-reviewed paper in The Lancet, the head of the Chinese Center for Disease Control and Prevention appeared to suggest he was concerned about their homegrown jabs not being effective enough, although Chinese state media quickly rolled back the comments. Vaccine makers Pfizer, BioNTech, and Moderna are all hoping to use mRNA in a wide range of other shots and drugs, after it proved so effective in the Covid-19 vaccines. Albert Bourla, Pfizer’s chief executive, told the Wall Street Journal last month that the technology had “dramatic impact and dramatic potential”. Even so, Biden has come under political pressure to waive Trips and allow developing countries to make their own copies of the vaccines that have been developed by pharmaceutical companies without fear of being sued for IP infringements. Several Democratic US lawmakers, including Earl Blumenauer, Rosa DeLauro, Jan Schakowsky, Bernie Sanders, Tammy Baldwin and Chuy García, have urged the Biden administration to support a temporary waiver of IP rights. A waiver has also been supported by a group of 175 former world leaders and Nobel laureates, who have urged the US to take “urgent action” to suspend IP. On Friday, the trade group Public Citizen’s Global Trade Watch and other advocacy groups said a petition in support of the waiver had been signed by 2m people.
国家研究机构手里也有一些关键知识产权,所以美国政府在新冠疫苗IP上是有不少话语权的,这也是为什么有人施压拜登政府 还有篇文章讲到这个. https://www.ft.com/content/d0c70cc2-0ffa-42dd-b0d0-0f76eeb273f0 The specific US government patent in question — US patent number 10,960,070, better known as the ’070 patent — relates to how the spike protein is stabilised in the vaccine, a technique that was developed by the NIH’s Vaccine Research Center. It is a key component of the mRNA vaccine jointly developed by Moderna and the NIH last year. Several companies have licensed the ’070 patent for their vaccines and pay the US government royalties, including Germany’s BioNTech, which developed its Covid-19 jab with Pfizer. According to several observers, Moderna has not licensed the patent and the US government has not enforced its rights. If the US government decides to sue Moderna, Moderna could conceivably owe over $1bn just for its sales through [to] the end of this year--Christopher Morten, New York University
这楼里这么多看不懂英文的吗？ A measure to allow countries to temporarily override patent rights for pandemic-related medical products was proposed at the World Trade Organization by India and South Africa in October, and has since been backed by almost 60 countries.
这楼里这么多看不懂英文的吗？ A measure to allow countries to temporarily override patent rights for pandemic-related medical products was proposed at the World Trade Organization by India and South Africa in October, and has since been backed by almost 60 countries. ca563 发表于 2021-04-25 12:05
这楼里这么多看不懂英文的吗？ A measure to allow countries to temporarily override patent rights for pandemic-related medical products was proposed at the World Trade Organization by India and South Africa in October, and has since been backed by almost 60 countries. ca563 发表于 2021-04-25 12:05
https://www.ft.com/content/fa1e0d22-71f2-401f-9971-fa27313570ab
Vaccine makers say IP waiver could hand technology to China and Russia Proposal to suspend patent rights comes as poorer countries struggle to obtain Covid doses
Vaccine makers have warned US officials that temporarily scrapping patents for Covid-19 shots would risk handing novel technology to China and Russia, according to people familiar with the talks.
As industry lobbying has escalated in Washington, companies have warned in private meetings with US trade and White House officials that giving up the intellectual property rights could allow China and Russia to exploit platforms such as mRNA, which could be used for other vaccines or even therapeutics for conditions such as cancer and heart problems in the future.
J&J, Pfizer, Moderna and Novavax did not respond to requests for comment. A measure to allow countries to temporarily override patent rights for pandemic-related medical products was proposed at the World Trade Organization by India and South Africa in October, and has since been backed by almost 60 countries.
While Donald Trump’s administration firmly opposed the waiver at the WTO, along with the UK, EU and Switzerland, US president Joe Biden’s top trade official Katherine Tai has rattled US pharmaceutical companies by appearing to put that position under review. Recommended Covid-19 vaccines Covid-19 vaccine tracker: the global race to vaccinate Tai and her staff have in recent weeks discussed the WTO’s IP rules with pharma companies, trade unions, advocacy groups and Seth Berkley, chief executive of the UN-backed vaccine alliance Gavi. Her office has said the agency was “exploring every avenue” and “evaluating the efficacy” of the waiver.
In a speech to a WTO meeting on vaccine equity earlier this month, Tai said that both the government and the private sector would need to do their part to “live up to” the “spirit” of the Trade-Related Aspects of Intellectual Property Rights (Trips) agreement, which was born out of the HIV crisis. “We hope to hear more today about how the market once again has failed in meeting the health needs of developing countries,” Tai told the WTO meeting. “As part of that, we have to consider what modifications and reforms to our trade rules might be necessary to reflect what we have learned.” Her speech has increased tension between pharma companies and the US trade representative (USTR), prompting one vaccine maker to complain to White House officials about Tai’s remarks to the WTO.
The White House did not respond to a request for comment. The USTR said its “top priority” was “saving lives” and that it was “working with our global partners to explore pragmatic and effective steps to surge the production and equitable distribution of vaccines”. The debate at the WTO about whether to temporarily waive intellectual protections comes amid concerns that rich countries are vaccinating their populations significantly faster than developing economies, which have struggled to obtain the required doses.
However, pharmaceutical companies insist they are already doing everything they can to expand production, and that global manufacturing bottlenecks, not patents, are slowing the rate at which vaccines are produced. The battle over IP comes as drugmakers are once again under pressure domestically, as drug pricing reform moves up the Biden administration's agenda. This includes proposals to peg drug prices to those in other industrialised nations, which are usually far cheaper, and allowing Medicare, the pension plan for older people, to negotiate prices.
The Chinese and Russian vaccines use different approaches from mRNA, the technology first deployed in an approved product for a Covid-19 vaccine. Recommended InterviewCovid-19 vaccines Vaccine patent gives US government ‘leverage’ over manufacturers While Russia’s Sputnik showed robust efficacy in a peer-reviewed paper in The Lancet, the head of the Chinese Center for Disease Control and Prevention appeared to suggest he was concerned about their homegrown jabs not being effective enough, although Chinese state media quickly rolled back the comments. Vaccine makers Pfizer, BioNTech, and Moderna are all hoping to use mRNA in a wide range of other shots and drugs, after it proved so effective in the Covid-19 vaccines.
Albert Bourla, Pfizer’s chief executive, told the Wall Street Journal last month that the technology had “dramatic impact and dramatic potential”. Even so, Biden has come under political pressure to waive Trips and allow developing countries to make their own copies of the vaccines that have been developed by pharmaceutical companies without fear of being sued for IP infringements.
Several Democratic US lawmakers, including Earl Blumenauer, Rosa DeLauro, Jan Schakowsky, Bernie Sanders, Tammy Baldwin and Chuy García, have urged the Biden administration to support a temporary waiver of IP rights. A waiver has also been supported by a group of 175 former world leaders and Nobel laureates, who have urged the US to take “urgent action” to suspend IP. On Friday, the trade group Public Citizen’s Global Trade Watch and other advocacy groups said a petition in support of the waiver had been signed by 2m people.
当然可能啊，什么都有可能
还有篇文章讲到这个.
https://www.ft.com/content/d0c70cc2-0ffa-42dd-b0d0-0f76eeb273f0
The specific US government patent in question — US patent number 10,960,070, better known as the ’070 patent — relates to how the spike protein is stabilised in the vaccine, a technique that was developed by the NIH’s Vaccine Research Center. It is a key component of the mRNA vaccine jointly developed by Moderna and the NIH last year.
Several companies have licensed the ’070 patent for their vaccines and pay the US government royalties, including Germany’s BioNTech, which developed its Covid-19 jab with Pfizer. According to several observers, Moderna has not licensed the patent and the US government has not enforced its rights.
If the US government decides to sue Moderna, Moderna could conceivably owe over $1bn just for its sales through [to] the end of this year --Christopher Morten, New York University
不仅仅是搞疫苗外交。还 TMD 在各大电视台上整天给民众洗脑，美帝 亡我之心不死。
这楼里这么多看不懂英文的吗？
A measure to allow countries to temporarily override patent rights for pandemic-related medical products was proposed at the World Trade Organization by India and South Africa in October, and has since been backed by almost 60 countries.
你再看看wto 躲在背后把别人当枪使 一向是某大国的传统
放弃专利 公开技术 多么熟悉的配方
关键是美国公司不担心印度南非弯道超车，只担心中俄把东西学去了，算不算意识形态挂帅，亡我之心不死？
换个国家还有人信，中国能忽悠得动印度？印度连中国的氧气都拒绝要呢
南非呢？你怎么就忽略了南非
印度自己也是仿制药大国 里面当然也有利益
美国确实不应该放弃专利！支持美国保护自己的权益！
咦，你断章取义还质疑别人的阅读能力？
就好像一群叫花子，其中一个叫花子a跟地主说，你看我们这么穷，你家的地无偿给我们大家种吧。但是大家都知道叫花子c人品不好，很可能用那地种罂粟，卖毒品挣大钱，然后再把别的叫花子的地都买了。
然后你说，你看这事实叫花子a的主意，大家总盯着c干嘛？
而且美国情报部门挖出这次全世界黑mRNA疫苗的主力是俄国，想必俄国也不会眼馋mRNA技术， 中国嘛一直担心这个不安全，会面瘫，中国有更安全的技术有P3实验室(高福语)，应该也不会眼馋这个疫苗。
所以到底是哪里出了问题？
这很难理解吗？跟朋友可以分享，跟敌人要划清界线。你把人家往死里骂，转过头来骂人家不把你当朋友给你分享自己的好东西，这难道不是精分？